Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript February 24, 2026
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.39.
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Conference Call. Please be advised that today’s call is being recorded. I will now turn the call over to Eva Stroynowski, Head of...
